Muvalaplin and Olpasiran Show Promise in Lowering Lp(a)

Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.

Related Keywords

Boston ,Massachusetts ,United States ,Amsterdam ,Noord Holland ,Netherlands ,Australia ,United Kingdom ,Monash ,South Australia ,Melbourne ,Victoria ,American ,Eli Lilly ,Louise Bowman ,Michellel Odonoghue ,Stephenj Nicholls ,University Of Oxford ,European Society Of Cardiology ,Harvard Medical School ,Amgen ,Medicines Company ,American Heart Association Scientific Sessions ,Monash University ,Astrazeneca ,Victoria Heart Institute ,Boehringer Ingelheim ,Novartis ,European Society ,New England Journal ,New Amsterdam Pharma ,Lipids ,Ipid Management ,Cv ,Ardiovascular ,Pcsk9 ,Roprotein Convertase Subtilisin Kexin Type 9 ,Grant ,Heart ,Low Ldl Cholesterol ,Ypobetalipoproteinemia ,Ow Low Density Lipoprotein Cholesterol ,Apolipoproteins ,Atherosclerosis ,Body Mass Index Bmi ,Cardiovascular Disease ,Vd Cardiovascular Disease ,Fatigue ,Genetics ,Hospitals ,Imbalance ,Interference ,Lipoproteins ,Liver ,Genomi ,